Thomas Glanzmann (CH) | New member of the Board of Directors to be elected at the Annual General Meeting on May 29, 2026
Thomas Glanzmann has more than 35 years of international leadership experience across the healthcare, consumer goods and industrial sectors. He has served as CEO of global publicly listed and non-listed companies and has extensive expertise in strategy, transformation, as well as financial and risk management.
Following his early career at Philip Morris and his long tenure at Baxter International – most recently as Senior Corporate Vice President and President of Baxter Bioscience – he went on to serve, among others, as a Managing Director at the World Economic Forum Davos, CEO of HemoCue and Gambro. He subsequently transitioned into an international portfolio career as an investor and non-executive board member.
He has served on the Board of Sulzer (2012 – 2018) and is currently a member of the Alcon Board. He is a Founder and Partner of US based Medical Technology Venture Partners. Most recently and until 2025, he also served as Executive Chairman and CEO of Grifols, a global Spanish public Healthcare Company.